Chemotherapy-induced cardiomyopathy

Cardiomyopathy is an adverse outcome of antineoplastic drug therapy that has become increasingly relevant in the management of cancer survivors. As the efficacy of anticancer treatments has improved, long-term outcomes are altered by the development of cardiotoxicity, which may be associated with an...

Full description

Saved in:
Bibliographic Details
Published in:Heart failure reviews 2015-11, Vol.20 (6), p.721-730
Main Authors: Higgins, Angela Y., O’Halloran, Thomas D., Chang, James D.
Format: Article
Language:English
Subjects:
Anthracyclines - adverse effects
Anthracyclines - therapeutic use
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biomarkers - analysis
Cardiology
Cardiomyopathies - chemically induced
Cardiomyopathies - diagnosis
Cardiotoxicity - prevention & control
Heart Failure - etiology
Humans
Magnetic Resonance Imaging
Medicine
Medicine & Public Health
Neoplasms - complications
Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiomyopathy is an adverse outcome of antineoplastic drug therapy that has become increasingly relevant in the management of cancer survivors. As the efficacy of anticancer treatments has improved, long-term outcomes are altered by the development of cardiotoxicity, which may be associated with an even worse prognosis than that of the underlying malignancy. From the research into mechanisms, prevention, and treatment, the specialized field of cardio-oncology has evolved, but the recognition and appropriate management of these patients is important for the general internist and general cardiologist as well. Although antineoplastic chemotherapy can cause multiple forms of cardiotoxicity, including arrhythmia, pericardial disease, valvular dysfunction, and myocardial ischemia, in this review we will focus on chemotherapeutic agents associated with cardiomyopathies, from the anthracyclines to newer, the so-called targeted agents such as tyrosine kinase inhibitors. We also review the diagnostic modalities for chemotherapy-induced cardiomyopathy as well as the prevention and treatment strategies which may prolong the lives of those suffering from cancer.
ISSN:1382-4147
1573-7322
DOI:10.1007/s10741-015-9502-y